
RA-9
CAS No. 919091-63-7
RA-9( —— )
Catalog No. M22045 CAS No. 919091-63-7
RA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 41 | Get Quote |
![]() ![]() |
10MG | 68 | Get Quote |
![]() ![]() |
25MG | 120 | Get Quote |
![]() ![]() |
50MG | 177 | Get Quote |
![]() ![]() |
100MG | 277 | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameRA-9
-
NoteResearch use only, not for human use.
-
Brief DescriptionRA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity.
-
DescriptionRA-9 is a potent and selective proteasome-associated inhibitor of deubiquitinating enzymes (DUBs), with favorable toxicity profile and anticancer activity. RA-9 selectively induces apoptosis in ovarian cancer cell lines.The characterization of RA-9 as a small-molecule inhibitor of proteasome-associated DUBs.?Treatment with RA-9 selectively induces onset of apoptosis in ovarian cancer cell lines and primary cultures derived from donors.?Loss of cell viability following RA-9 exposure is associated with an unfolded protein response as mechanism to compensate for unsustainable levels of proteotoxic stress.?In vivo treatment with RA-9 retards tumor growth, increases overall survival, and was well tolerated by the host.
-
In VitroCell Viability Assay Cell Line:Cisplatin-sensitive ovarian cancer cell lines TOV-21G and ES-2, Cisplatin-resistant ovarian cancer cell lines HEY and OVCAR-3, primary ovarian cancer cellsConcentration:10, 20, 30 μM Incubation Time:48 hours Result:Compromised the viability of ovarian cancer cells in a dose-dependent fashion.Cell Cycle Analysis Cell Line:ES-2 cells Concentration:1.25, 5 μM Incubation Time:18 hours Result:Resulted in a dose-dependent increase in the fraction of ES-2 cells in the G2-M cell cycle phase.Western Blot Analysis Cell Line:ES-2, SKOV-3 and TOV-21G ovarian cancer cells Concentration:5 μM Incubation Time:0-24 h Result:Caused a time-dependent increase in the steady levels of the early ER-stress marker GRP-78, as well as the late ER-stress markers IRE1-α and Ero1L-α.
-
In VivoAnimal Model:Six-week-old female immunodeficient (NCr nu/nu) mice Dosage:5 mg/kg Administration:I.p; one-day on, two-days off Result:Significant reduction in tumor burden at day 12.
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis|deubiquitinating enzymes (DUBs)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number919091-63-7
-
Formula Weight365.34
-
Molecular FormulaC19H15N3O5
-
Purity>98% (HPLC)
-
SolubilityDMSO:4 mg/mL (10.95 mM; ultrasonic and warming and heat to 80°C)
-
SMILES[O-][N+](=O)c1ccc(\C=C2/CNC\C(=C/c3ccc(cc3)[N+]([O-])=O)C2=O)cc1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
KT5823
KT5823 is a selective and potent cGMP-dependent protein kinase (PKG) inhibitor with inhibitory effects on PKA and PKC.KT5823 increases thyroid-stimulating hormone-induced (Na+/I- symporter) NIS expression and iodide ion uptake by modulating sodium iodide symporter protein expression and activity in thyroid cells. KT5823 induces apoptosis.
-
Urolithin C
Urolithin C is a gut metabolite of ellagic acid. Urolithin C induces apoptosis in PC12 cells through a mitochondria-mediated pathway.
-
AAPK-25
AAPK-25, a potent and selective dual inhibitor of Aurora/PLK, causes mitotic delay and cell arrest in prometaphase, via phosphorylation of the biomarker histone H3Ser10, followed by a surge in apoptosis.